Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Breast cancer marker receives diagnostic and therapeutic patent approval
March 2nd, 2006
Genesis Bioventures, Inc., (GBIW) (GBI) announced that Mammastatin, the breast cancer marker exclusively licensed to its wholly owned subsidiary, Biomedical Diagnostics, LLC (Biomedical), has been granted additional patent protection through a deed of letters patent recently issued to the University of Michigan by the Australian Patent Office. Biomedical is currently developing the Mammastatin technology for use in its Mammastatin Serum Assay (MSA), a breast cancer risk assessment tool. "We are very pleased with this positive development for Biomedical," said Douglas C. Lane of Experigen Management Co. "Not only does the patent grant allow Biomedical...
Source: Women's Health Weekly (2006-03-02)
|
